{"id":"lofexidine-hcl","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Bradycardia"}]},"_chembl":{"chemblId":"CHEMBL17860","moleculeType":"Small molecule","molecularWeight":"259.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lofexidine binds to alpha-2 adrenergic receptors in the brain, suppressing the release of norepinephrine and reducing the hyperadrenergic state characteristic of opioid withdrawal. This mechanism dampens withdrawal-related symptoms such as anxiety, agitation, muscle aches, and autonomic hyperactivity without producing opioid-like euphoria or dependence.","oneSentence":"Lofexidine is an alpha-2 adrenergic agonist that reduces noradrenergic hyperactivity in the central nervous system to alleviate opioid withdrawal symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:45.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid withdrawal"}]},"trialDetails":[{"nctId":"NCT05995535","phase":"PHASE2","title":"Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-01-01","conditions":"Opiate Withdrawal Syndrome, Opioid Use","enrollment":150},{"nctId":"NCT04325659","phase":"PHASE2, PHASE3","title":"An Innovative Intervention for OUD Treatment","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-11-15","conditions":"Opioid-Related Disorders, Opioid Dependence, Opioid Addiction","enrollment":46},{"nctId":"NCT05712707","phase":"PHASE1, PHASE2","title":"Sublingual Dexmedetomidine for Treating Opioid Withdrawal","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2023-02-28","conditions":"Opioid Use Disorder, Opioid Withdrawal","enrollment":160},{"nctId":"NCT05511909","phase":"PHASE2","title":"Evaluating Buspirone to Treat Opioid Withdrawal","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-12-15","conditions":"Opioid Use Disorder, Opioid Withdrawal, Opioid Craving","enrollment":100},{"nctId":"NCT06047834","phase":"PHASE2","title":"Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioCorRx Pharmaceuticals Inc","startDate":"2023-10-02","conditions":"Opioid Withdrawal (Disorder)","enrollment":24},{"nctId":"NCT05027919","phase":"PHASE2","title":"Assessing a Clinically-meaningful Opioid Withdrawal Phenotype","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-12-01","conditions":"Opioid Withdrawal, Opioid Use Disorder, Opioid Craving","enrollment":60},{"nctId":"NCT06711640","phase":"PHASE1","title":"A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects","status":"WITHDRAWN","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2025-06","conditions":"Opioid Withdrawal (Disorder), Opioid Use Disorder","enrollment":""},{"nctId":"NCT05053503","phase":"NA","title":"Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder","status":"COMPLETED","sponsor":"Spark Biomedical, Inc.","startDate":"2022-05-27","conditions":"Opioid-use Disorder, Opioid Withdrawal","enrollment":108},{"nctId":"NCT04360681","phase":"PHASE2","title":"Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans","status":"RECRUITING","sponsor":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","startDate":"2021-03-09","conditions":"Post Traumatic Stress Disorder, Opioid-use Disorder","enrollment":120},{"nctId":"NCT03718065","phase":"PHASE2","title":"Impact of Lofexidine on Stress, Craving and Opioid Use","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2019-06-26","conditions":"Opioid-use Disorder, Opiate Dependence","enrollment":112},{"nctId":"NCT04070157","phase":"PHASE2","title":"Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal","status":"TERMINATED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2019-08-02","conditions":"Opioid Withdrawal (Disorder)","enrollment":4},{"nctId":"NCT04218240","phase":"PHASE2","title":"Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-12-17","conditions":"Opioid Withdrawal","enrollment":90},{"nctId":"NCT05569031","phase":"PHASE4","title":"Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2019-01-01","conditions":"Opiate Withdrawal Syndrome","enrollment":52},{"nctId":"NCT04188730","phase":"PHASE1","title":"A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2021-02-16","conditions":"Normal Healthy Volunteers","enrollment":16},{"nctId":"NCT01863186","phase":"PHASE3","title":"Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2013-06","conditions":"Opioid Dependence, Acute Opioid Withdrawal Syndrome","enrollment":603},{"nctId":"NCT02363998","phase":"PHASE3","title":"Open-Label, Safety Study of Lofexidine","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2015-02","conditions":"Opioid Withdrawal","enrollment":286},{"nctId":"NCT04126083","phase":"PHASE4","title":"Lofexidine for Adults Undergoing Lumbar Spine Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-09-01","conditions":"Opioid Withdrawal","enrollment":6},{"nctId":"NCT04056182","phase":"PHASE2","title":"Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2019-09-01","conditions":"Opioid-use Disorder","enrollment":20},{"nctId":"NCT01020019","phase":"PHASE2, PHASE3","title":"Combined Pharmacotherapy for Cannabis Dependency","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2010-01","conditions":"Cannabis Dependence, Marijuana Dependence","enrollment":156},{"nctId":"NCT01820442","phase":"PHASE1","title":"Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2013-03","conditions":"Opioid Dependence, Buprenorphine Withdrawal Syndrome","enrollment":30},{"nctId":"NCT02681198","phase":"PHASE1","title":"Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2016-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT01558934","phase":"PHASE1","title":"Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2012-02","conditions":"Opioid Dependence, Methadone Withdrawal Syndrome","enrollment":6},{"nctId":"NCT02318836","phase":"PHASE1","title":"Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2014-06","conditions":"Liver Failure","enrollment":24},{"nctId":"NCT01437306","phase":"PHASE1","title":"Lofexidine Food Effect Study in Healthy Volunteers","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2011-10","conditions":"Healthy","enrollment":13},{"nctId":"NCT02801357","phase":"PHASE1","title":"Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2016-06","conditions":"Substance Withdrawal Syndrome, Opiate Addiction, Opiate Dependence","enrollment":10},{"nctId":"NCT02446002","phase":"PHASE1","title":"Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy Subjects","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2015-05","conditions":"Healthy","enrollment":25},{"nctId":"NCT02313103","phase":"PHASE1","title":"Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2014-11","conditions":"Renally Impaired Subjects","enrollment":16},{"nctId":"NCT01629446","phase":"PHASE1","title":"Lofexidine Mass Balance in Volunteers","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2012-05","conditions":"Normal Healthy Volunteers","enrollment":6},{"nctId":"NCT01310296","phase":"PHASE1","title":"Lofexidine ADME & Mass Balance in Volunteers","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2011-07","conditions":"Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product","enrollment":12},{"nctId":"NCT01650649","phase":"PHASE1","title":"Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2012-07","conditions":"Opioid Dependence, Methadone Withdrawal Syndrome","enrollment":27},{"nctId":"NCT00000345","phase":"PHASE1","title":"Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1996-04","conditions":"Opioid-Related Disorders","enrollment":""},{"nctId":"NCT00032942","phase":"PHASE3","title":"Lofexidine for Opiate Withdrawal - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-04","conditions":"Opioid-Related Disorders","enrollment":66},{"nctId":"NCT00000358","phase":"PHASE1","title":"Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"","conditions":"Opioid-Related Disorders, Substance-Related Disorders","enrollment":""},{"nctId":"NCT00218530","phase":"PHASE1","title":"Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2003-03","conditions":"Heroin Dependence","enrollment":""},{"nctId":"NCT00000354","phase":"PHASE1","title":"Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1996-07","conditions":"Opioid-Related Disorders, Substance-Related Disorders","enrollment":""},{"nctId":"NCT01148992","phase":"PHASE1","title":"Interactions Between Intravenous (IV) Cocaine and Lofexidine","status":"TERMINATED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2010-08","conditions":"Cocaine Related Disorders","enrollment":16},{"nctId":"NCT01675648","phase":"PHASE4","title":"Lofexidine for Inpatient Opiate Detox in Singapore","status":"COMPLETED","sponsor":"Institute of Mental Health, Singapore","startDate":"2012-08","conditions":"Opiate Dependent Patients Who Are Undergoing Inpatient Detoxification in Singapore","enrollment":112},{"nctId":"NCT00142909","phase":"PHASE2","title":"Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-02","conditions":"Opioid-Related Disorders","enrollment":86},{"nctId":"NCT00373503","phase":"PHASE2","title":"Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2005-08","conditions":"Marijuana Dependence","enrollment":8},{"nctId":"NCT00235729","phase":"PHASE3","title":"Lofexidine for Inpatient Opiate Detox","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2006-06","conditions":"Opiate Addiction","enrollment":264}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"lofexidine HCl","genericName":"lofexidine HCl","companyName":"USWM, LLC (dba US WorldMeds)","companyId":"uswm-llc-dba-us-worldmeds","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lofexidine HCl is used to treat opioid withdrawal symptoms and opioid use disorder. It is administered as part of a clinical study to assess its efficacy and safety in managing opioid withdrawal and use disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}